2022
Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis
Gooderham M, Pinter A, Ferris L, Warren R, Zhan T, Zeng J, Soliman A, Kaufmann C, Kaplan B, Photowala H, Strober B. Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis. Journal Of The European Academy Of Dermatology And Venereology 2022, 36: 855-865. PMID: 35174556, PMCID: PMC9314097, DOI: 10.1111/jdv.18010.Peer-Reviewed Original ResearchConceptsDermatology Life Quality IndexSevere plaque psoriasisHealth-related qualityRisankizumab treatmentPlaque psoriasisAbsolute PASIDLQI 0/1Psoriasis AreaDLQI scoreAbsolute PASI scoreAbsolute Psoriasis AreaUstekinumab-treated patientsMean DLQI scoreSeverity Index (PASI) improvementLife Quality IndexHigh ratePASI levelsPatients' HRQoL.PASI scoreMedian timeDurable efficacyPat ientsRisankizumabPASIPatients
2021
27596 Improvement in absolute psoriasis area and severity index through 5 years of continuous treatment with guselkumab in the VOYAGE 1 trial
Puig L, Strober B, Tsai T, Thaçi D, Gooderham M, Miller M, Yang Y, You Y, Shen Y, Blauvelt A. 27596 Improvement in absolute psoriasis area and severity index through 5 years of continuous treatment with guselkumab in the VOYAGE 1 trial. Journal Of The American Academy Of Dermatology 2021, 85: ab154. DOI: 10.1016/j.jaad.2021.06.629.Peer-Reviewed Original Research
2020
An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis
Strober B, Gottlieb A, Thaçi D, Puig L, Colombo M, Kundu S, Kisa R, Banerjee S. An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. SKIN The Journal Of Cutaneous Medicine 2020, 4: s73. DOI: 10.25251/skin.4.supp.73.Peer-Reviewed Original ResearchAbsolute Psoriasis AreaPhase 2 trialPsoriasis AreaSeverity IndexKinase 2 inhibitorTyrosine kinase 2 inhibitorAn Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis
Strober B, Gottlieb A, Thaçi D, Puig L, Colombo M, Kundu S, Kisa R, Banerjee S. An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. SKIN The Journal Of Cutaneous Medicine 2020, 4: s27. DOI: 10.25251/skin.4.supp.27.Peer-Reviewed Original ResearchAbsolute Psoriasis AreaPhase 2 trialPsoriasis AreaSeverity IndexKinase 2 inhibitorTyrosine kinase 2 inhibitor